Earnings get underway, plus this tiny biotech is soaring

Today’s big movers inside                                                                                                                                                                                                                                                                                                                                                                                                                 April 12, 2024 | [Read Online]( Earnings get underway, plus this tiny biotech is soaring In partnership with Good day, 360! Here are our top investing ideas today. Please join us today for live trading and chat in the [Market Master’s Room](. Be the best prepared trader on the Street (and have the most fun 🎉)! FOCUS LIST🔎 PXMD - Up over 90% in the premarket after update and achievement of key milestone in the development of PAX-101 NXPL - Up over 70% in pre after reporting increased revenues, record annual margins and $26.3 million in cash OCX - Up over 11% in pre after reporting full year 2023 results How To Spot the Gamma Trigger Watch [this video]( to see how Jeff has fused $15,000 worth of Artificial Intelligence with his blockbuster Gamma Trigger System to deliver 330 trade plans with triple-digit or more potential in a little over a year! Jeff is taking the mystery out of Artificial Intelligence and doing all the hard work for you, because He Does Not want you to be left behind. [Embrace the future NOW to get his THREE best AI-generated, high-probability trades DAILY.]( This BLOWOUT SALE ends Midnight PST. HOTLIST🔥 PXMD - Up over 90% in the premarket after update and achievement of key milestone in the development of PAX-101 PaxMedica Inc. (PXMD) is a clinical stage biopharmaceutical company that focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. In the after-hours yesterday, the [company announced]( that it had completed the execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin. This achievement is an important milestone to enabling a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA), which is currently planned for Q4 2024, and for the potential commercial availability in the U.S. of the first and only form of suramin for the treatment of Stage 1 Human African Trypanosomiasis (HAT), caused by Trypanosoma brucei rhodesiense, a fatal, neglected tropical disease, if approved by the FDA. The stock traded up over 90% in the pre-market on the news. The $0.90 area acted as resistance in the pre-market and will be an important level to watch. Above it, targets to the upside are $0.98 and then the after-hours high at $1.07. Beyond that $1.15, $1.29 and $1.65 come into play. Below $0.90, targets to the downside are $0.80, $0.75, $0.60 and $0.50. NXPL - Up over 70% in pre after reporting increased revenues, record annual margins and $26.3 million in cash NextPlat Corp (NXPL) together with its subsidiaries, provides mobile satellite services (MSS) solutions for satellite-enabled voice, data, personnel and asset tracking, machine-to-machine, and Internet of Things (IoT) connectivity services in Europe, North America and internationally. In the after-hours yesterday, the [company reported]( revenues for the full year ended December 31, 2023 of approximately $37.8 million, an increase of over 222% vs $11.7 million for the full year ending December 31, 2022. Gross margins for the full year ended December 31, 2023, increased significantly to 30%, up from 21% reported for the year ended December 31, 2022. The Company ended the 2023 fiscal year with approximately $26.3 million in cash. The stock traded up over 70% in the pre-market in reaction to the earnings announcement. The $2.40 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $2.70, $2.80 and then the pre-market high at $2.85. Beyond that $3.05, $3.40 and $4.20 come into play. Below $2.40, targets to the downside are $2.30, $2.20, $2, $1.60 and then a gap fill at $1.50. *sponsored by MaxAI Me MaxAI.me - Smart Browsing with 1-Click AI [MaxAI.me](—where AI meets your browser. Instantly enhance web browsing with article summaries, email crafting, and AI-powered web searches. Ranked #1 of the day and the week on ProductHunt. [Discover why 1M+ users trust us. Install now!]( OCX - Up over 11% in pre after reporting full year 2023 results OncoCyte Corporation (OCX) is a molecular diagnostics company that researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. In the after-hours yesterday, the [company reported]( full year 2023 revenues of $1.5 million, an increase of 57% compared to the full year 2022, due to increased revenue from Pharma Services. The stock traded up over 11% in the pre-market in reaction to the results. The $3.25 area has acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $3.50, $5, $4.50, $5, $5.50 and then the after-hours high at $6.50. Below $3.25 there is a gap till at $2.97 then $2.80 and $2.60 come into play. MARKET NEWS 📰 Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [( *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America